There is something clarifying about turning 40. Not in a crisis sense — I'm not trying to reverse anything or chase a version of myself from twenty years ago. But in a quietly practical sense, I found myself looking at my face differently. Not with alarm, but with clinical interest. The same assessment I carry out on my patients every week, turned on myself.
What I noticed was not dramatic. It never is at this stage, which is exactly the point. A slight softening through the midface. A little less definition at the jaw. The temples, which I've always watched carefully in patients, beginning their slow retreat. Nothing that would register to anyone else. But I know what these early changes mean structurally, and I know where they go if left alone.
So I started Sculptra. And I want to explain why — both the personal reasoning and the clinical evidence behind the decision — because I think it's one of the most misunderstood treatments I offer.
What actually happens to the face in your 40s
Collagen loss begins earlier than most people realise — around the mid-twenties, at approximately 1% per year. By the time visible changes appear, a significant amount of structural support has already been lost. What we see on the surface — softening, laxity, hollowing — is the end result of a process that has been quietly happening for fifteen years or more.
The 40s bring additional factors. Oestrogen decline — which for many women begins in perimenopause during this decade — accelerates skin thinning and collagen degradation significantly. Oestrogen plays a direct role in stimulating collagen synthesis and maintaining skin thickness; as levels drop, the rate of loss increases. Bone resorption also begins to affect facial structure, particularly around the orbital rim, the jaw and the midface — causing the soft tissue above to lose its scaffolding and migrate downward.
Volume loss in the face is not uniform. The temples hollow first, often invisibly. Fat pads in the cheek descend and separate. The midface flattens. The under-eye area deepens. These changes happen in a predictable pattern — and understanding that pattern is what makes early intervention clinically sensible rather than cosmetically vain.
"It is significantly easier to maintain facial structure than it is to restore it. That is not a marketing position — it is a basic principle of tissue biology."
Why I decided not to wait
This is the question I am most often asked about Sculptra, and the answer I give my patients is the same one I applied to myself: it is significantly easier to maintain facial structure than it is to restore it. That is not a marketing position. It is a basic principle of tissue biology.
When I look at the patients who achieve the most natural, sustainable results with Sculptra, they are almost always the ones who started before the changes became dramatic — who chose to support what was already there rather than replace what had already gone. The patients who come to me at 55 or 60 with significant volume deficit can still benefit from Sculptra, but they need more product, more sessions, and more time. The results, though real, require more work to achieve and maintain.
Starting at 40, with early changes, means working with the body's existing biology while it is still relatively responsive. My collagen-producing fibroblasts are still active. My tissue quality is still good. Sculptra at this stage is asking the body to do something it is still capable of doing well — producing collagen — rather than trying to compensate for years of loss after the fact.
There is also something important about the nature of the treatment itself. Sculptra does not add volume the way a filler does. It asks your body to produce its own collagen in response to the presence of poly-L-lactic acid microspheres. The result — when it comes — is made of you. It integrates with your tissue in a way that no external substance can replicate. That quality of result is worth starting early to achieve.
What the current evidence actually says
Sculptra (poly-L-lactic acid, or PLLA) has one of the longest and most well-documented safety records of any injectable aesthetic treatment. It was first approved by the FDA in 2004 for facial lipoatrophy in HIV patients — a population with severe, medically significant facial volume loss — which meant the early evidence base was built under rigorous conditions with genuine clinical need.
What the research shows
Duration: Multiple clinical studies report results lasting 25 months or more, with some evidence of benefit beyond two years. The APEX study, a key long-term trial, demonstrated sustained improvement in nasolabial fold severity at 25 months post-treatment in the majority of patients.
Mechanism: Histological analysis confirms that PLLA stimulates new collagen synthesis by activating fibroblasts — the cells responsible for producing collagen, elastin and hyaluronic acid in the dermis. This has been demonstrated in biopsy studies showing genuine neocollagenesis, not simply a volumising effect from the product itself.
Safety: The most significant adverse event associated with Sculptra — subcutaneous nodule formation — is closely linked to technique and dilution. With the appropriate dilution protocol (5ml or more per vial), the 5-5-5 post-treatment massage protocol, and avoidance of superficial injection planes, nodule rates are low. The evidence strongly supports technique as the primary determinant of safety outcomes.
Combination use: More recent evidence supports Sculptra as part of a multimodal treatment approach — combining it with HA filler for immediate structural definition, and skin quality treatments (such as Profhilo or skin boosters) for surface improvement that Sculptra alone does not address.
What I find compelling about the evidence is not just the efficacy data, but the mechanism. We are not masking the signs of ageing. We are addressing one of their root causes — the progressive loss of the collagen scaffold that supports facial structure. That distinction matters to me, both as a practitioner and as a patient.
What I'm expecting — and what I'm not
I want to be transparent about this, because I think unrealistic expectations are one of the biggest problems in aesthetics.
I am not expecting to look dramatically different. I am not expecting to look younger in any obvious sense. I am not expecting anyone to notice. What I am investing in is the slower, less visible process of maintaining the structural integrity of my face over the next decade — so that the changes that would otherwise accumulate gradually, do so more slowly.
I am also prepared for what the process involves. Sculptra is not a one-session treatment. I will have a course of three sessions, spaced six weeks apart. I will see very little in the first weeks. The improvement will emerge gradually over three to six months as new collagen forms. I will follow the 5-5-5 massage protocol diligently after each session. And I know from treating hundreds of patients with this product that patience is not optional — it is built into the mechanism of how it works.
"I am investing in the slower, less visible process of maintaining the structural integrity of my face over the next decade. Not in looking different — in ageing well."
I will also continue everything else. Vitamin C and SPF every morning. Retinoids three nights a week. Adequate protein. The home skincare regime that supports the same collagen synthesis that Sculptra is trying to stimulate. Because in-clinic treatments and home skincare are not alternatives — they work on the same biology, and they work best together.
Forty felt like the right moment to make this commitment. Not because something went wrong, but because I understood what was quietly beginning to happen — and I had both the knowledge and the access to do something sensible about it.
I will share how it goes.
Interested in whether Sculptra is right for you?
Book a consultation and Clare will carry out a full facial assessment, explain what she sees and what she recommends — with no obligation to proceed.
Book a Consultation